Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cohance Lifesciences Limited (COHANCE.NS)
Hyderabad, IN
Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.43% | -8.18% | +24.92% | +41.06% | -27.67% | -15.78% | -58.74% | -6.17% | -13.93% | +164.17% | +164.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+89.4% ★ Q1'26: +54.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-55.2% Q1'26: -68.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+7.3% Q1'26: +27.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+10.6% Q1'26: +7.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.2% Q1'26: +2.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+49.7% Q1'26: +48.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.94× Q1'26: 1.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 8 Rev. Ana. 5 EPS Ana. |
Mar 2027 6 Rev. Ana. 6 EPS Ana. |
Mar 2028 9 Rev. Ana. 7 EPS Ana. |
Mar 2029 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
10.51B
est: 10.90B (-3.5%)
|
11.98B
est: 23.00B (-47.9%)
|
22.55B
20.87B – 28.06B
-2.0% YoY
|
25.24B
24.16B – 26.74B
+11.9% YoY
|
29.81B
28.88B – 30.74B
+18.1% YoY
|
35.23B
35.23B – 35.23B
+18.2% YoY
|
| EBITDA |
4.09B
est: 4.43B (-7.6%)
|
4.06B
est: 9.34B (-56.6%)
|
9.16B
8.47B – 11.40B
-2.0% YoY
|
10.25B
9.81B – 10.86B
+11.9% YoY
|
12.10B
11.73B – 12.48B
+18.1% YoY
|
14.31B
14.31B – 14.31B
+18.2% YoY
|
| EBIT |
3.54B
est: 3.97B (-10.6%)
|
3.28B
est: 8.37B (-60.8%)
|
8.21B
7.60B – 10.21B
-2.0% YoY
|
9.18B
8.79B – 9.73B
+11.9% YoY
|
10.85B
10.51B – 11.19B
+18.1% YoY
|
12.82B
12.82B – 12.82B
+18.2% YoY
|
| Net Income |
3.00B
est: 3.30B (-9.0%)
|
2.68B
est: 5.45B (-50.9%)
|
1.79B
1.63B – 4.79B
-67.1% YoY
|
3.07B
2.31B – 3.13B
+71.3% YoY
|
4.32B
3.41B – 4.92B
+40.8% YoY
|
5.12B
5.01B – 6.86B
+18.4% YoY
|
| SGA |
1.40B
est: 1.29B (+8.0%)
|
2.56B
est: 2.73B (-6.0%)
|
2.67B
2.47B – 3.33B
-2.0% YoY
|
2.99B
2.86B – 3.17B
+11.9% YoY
|
3.53B
3.42B – 3.64B
+18.1% YoY
|
4.18B
4.18B – 4.18B
+18.2% YoY
|
| EPS |
11.80
est: 12.90 (-8.5%)
|
10.52
est: 14.08 (-25.3%)
|
5.78
4.24 – 12.51
-59.0% YoY
|
7.16
6.03 – 8.17
+24.0% YoY
|
10.86
8.90 – 12.86
+51.7% YoY
|
15.50
13.08 – 17.91
+42.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.02% | 3.62M | 0.07% |
| 2 | State Street SPDR Portfolio MSCI Global Stock Market ETF SPGM | 0.00% | 46.7K | 0.09% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vivek Sharma | Executive Chairman | 72M | male |
| Umang Vohra | Executive Chairman | 72M | male |
| Declan Ryan | Chief Commercial Officer | — | — |
| Gaurav Narain Bahadur | Chief Human Resources Officer | — | male |
| Gunjan Singh | Head of API Plus Business | — | male |
| Himanshu Agarwal | Chief Financial Officer | — | male |
| K. Nagendra Babu | Chief Quality & Compliance Officer | — | — |
| K.P Ravinatha Shetty | Platform Chief Operating Officer | — | male |
| Sisir Kumar Mishra | Company Secretary & Compliance Officer | — | male |
| Sunil Kumar-Ramashrya Singh | Chief Quality Officer | — | — |
| Amrit Singh | Head of Specialty Chemicals | — | male |
| Yann D'Herve | Chief Executive Officer of CDMO Business | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for COHANCE.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
